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Abstract
Vaccination with J8-DT, a leading GAS vaccine candidate, results in protective immunity in mice. Analysis of immunologic
correlates of protection indicated a role of J8-specific antibodies that were induced post-immunization. In the present study,
several independent experimental approaches were employed to investigate the protective immunological mechanisms
involved in J8-DT-mediated immunity. These approaches included the passive transfer of mouse or rabbit immune serum/
antibodies in addition to selective depletion of T-cell subsets prior to bacterial challenge. Passive transfer of J8-DT
antiserum/antibodies from mice and rabbits conferred significant resistance against challenge to mice. To exclude the
possibility of involvement of other host immune factors, the studies were repeated in SCID mice, which highlighted the
need for an ongoing immune response for long-lived protection. Depletion of CD4
+ and CD8
+ T-cell subsets confirmed that
an active de novo immune response, involving CD4
+ T-helper cells, is required for continued synthesis of antibodies
resulting in protection against GAS infection. Taken together these results indicate an involvement of CD4
+ T-cells in J8-DT-
mediated protection possibly via an ability to maintain antibody levels. These results have considerable relevance to the
development of a broad spectrum passive immunotherapy for GAS disease.
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Introduction
Group A streptococcus (GAS) is a Gram-positive bacterial
pathogen responsible for a wide variety of diseases ranging from
self-limiting generally benign conditions such as streptopcoccal
pharyngitis and pyoderma to invasive diseases including necrotis-
ing fasciitis. However, of most concern are the post infectious
sequelae of rheumatic fever/rheumatic heart disease and chronic
renal disease. To date, GAS vaccine development has primarily
focussed on the M-protein. The M-protein is a cell surface protein
that is highly variable at the amino terminus (serotypic
determinants) but is highly conserved at the carboxyl terminus.
Development of a vaccine for group A streptococcus (GAS), has
been hampered due to a number of serotypic variants of the M-
protein and the possibility of cross-reactivity of potential vaccine
candidates with host tissues. However, we have previously
identified a minimal B-cell epitope from the conserved region of
M-protein of GAS and demonstrated its protective potential [1,2].
The immune response to this minimal B-cell epitope, referred to as
J8, was found to be genetically restricted and J8 was nonimmuno-
genic in an outbred population. To overcome this non-
responsiveness, the peptide J8 was conjugated to the carrier
protein, diphtheria toxoid (DT) [3]. Carrier proteins such as DT
stimulate T-helper cells which co-operate with B-cells to enable
them to respond to the hapten by providing accessory signals.
The conjugated vaccine candidate, J8-DT, formulated with the
human compatible adjuvant, alum, was shown to be protective in
inbred and outbred mouse strains [3]. Evidence that antibodies
had a role in vaccine mediated immunity came from the observed
positive correlation between high J8-specific IgG titres and mouse
survival [3]. Therefore, the J8-specific antibody response was
considered to be important in protection against GAS infection.
Apassivetransfersystemhasbeenusedinthisstudytoconfirmthe
role of antibodies in protection and also to investigate the potential
therapeutic utility of antibodies for treating GAS infections. Passive
immunization with antibodies or antiserum has been shown to be
protective in a number of viral, bacterial and parasitic models [4–8].
Therapeutic antibodies may play an important role in treating
infectionscausedbydrug resistantpathogensaswellaspathogensfor
which no antimicrobial drug is available. Outcomes of clinical
studies to date using IVIG treatment for invasive GAS disease have
been variable [9,10]. The sources of IVIG for these studies vary and
levels of anti-streptococcal antibodies poorly defined. Furthermore,
the immunocompetence of the recipients and what effect if any, this
may have on the clinical outcome of the therapy has not been
ascertained. To investigate the potential of J8-specific antibodies and
the role of the recipient’s immune system in any therapeutic effect, a
passive transfer system was studied in a mouse model in which
antibody dosing and the role of host T and B lymphocytes were
determined.
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I. Mice
Four to six week old female BALB/c, B10.BR or SCID mice
were purchased from The Animal Resource Centre, Perth,
Western Australia. All animal protocols used were approved by
the Institute’s ethics committee (Queensland Institute of Medical
Research Animal Ethics Committee) in accordance with National
Health and Medical Research Council (NHMRC) of Australia
guidelines.
II. Peptide synthesis and conjugation to a peptide carrier
The peptide J8 (sequence QAEDKVKQSREAKKQVE-
KALKQLEDKVQC) was synthesised as described elsewhere
[11] and purified using high-performance liquid chromatography.
Peptide was conjugated via a C-terminal cysteine residue to DT
(CSL, Australia), using 69-maleimido-caproyl n-hydroxy succini-
mide (MCS), as described by Coligan et al. [12].
III. Immunization of mice
Cohorts of 20–30 BALB/c mice were subcutaneously immunized
at the tail base on day 0 with 30 ug of J8-DT or DT adsorbed on
alum. The antigens diluted in PBS were adsorbed onto alum at
room-temperature for one hour with slow mixing before being
injected into mice. To control for the effect of the adjuvant, parallel
cohorts of mice were given PBS in alum. All the groups also received
three subsequent boosts on day 21, 28 and 35. In some studies
B10.BR mice (inbred H-2
k background) were used for J8
immunization. Peptides (peptide alone or peptide conjugated to
DT) were administered subcutaneously in a volume of 50 ul at the
tail base to B.10.BR mice. Each mouse received a total of 30 ug of
immunogen (free peptide or conjugated peptide) emulsified 1:1 in
CFA (Sigma, USA). Control mice received PBS emulsified in CFA
(PBS/CFA). All the groups also received three subsequent boosts on
day 21, 28 and 35 in PBS. In some studies, post immunization, mice
weredepletedofCD4
+orCD8
+T-cellspriortochallengewithGAS.
Serum samples were collected on day 20, 27, 34 and 42 and IgG
concentrations and/or titers measured by ELISA [2].
IV. Preparation of J8 or J8-DT immune serum
High titer (titer .10
6) immune sera were collected from
immunized and control mice periodically. A week after the last
boost (day 42), the mice were bled by cardiac puncture. The blood
was allowed to clot at room temperature for 30 minutes followed
by overnight storage at 4uC to enable the clot to retract. The clot
was removed and supernatant was spun at 3000 rpm for
10 minutes. After spinning, the serum was collected and stored
at 220uC until used. To avoid antibody aggregation, the serum
samples were sonicated under cold conditions before being
transferred into the recipient mice [13].
V. Passive transfer of immune serum and GAS challenge
The pooled serum (from each group) was transferred intraperi-
toneally into the BALB/c, SCID or B10.BR mice in three doses of
0.5 ml each on day 21, 0 and +1 relative to the day of challenge.
Some cohorts of SCID mice received additional doses that were
administered post-challenge on day 3, 5 and 8. Two hours after the
second administration of antiserum/antibodies, on day 0, serum
samples were collected to confirm the success of serum transfer by
measuring antigen specific IgG levels in the recipient mice.
On day 0 the recipient mice were challenged intraperitoneally
with a predetermined dose of M1 GAS as described previously [3].
Following challenge, the mice were closely observed and their
survival monitored on a regular basis for 10–15 days.
VI. Production, purification and passive transfer of rabbit
IgG
Antibodies to J8-DT or to DT were raised in rabbits at IMVS,
Adelaide, South Australia. Two rabbits (New Zealand white, males
6–8 weeks) were vaccinated subcutaneously multiple times using
0.5 mg of J8-DT or DT antigen preparation in alum. Following
primary immunization, four subsequent boosts were given at
monthly intervals and serum samples were collected to measure
antibodies to J8. At the end of the boosting period a terminal bleed
was conducted and serum samples were used to purify IgG
antibodies as described below.
Rabbit IgG were purified using protein-G sepharose column
(GE Healthcare, USA). Briefly, rabbit antisera were diluted 1:2
and passed through protein G columns enabling antibodies to bind
to the column. The antibodies were then eluted using glycine-HCl
buffer (pH 2.7), neutralized using Tris-HCl (pH 9.0), dialysed and
concentrated. The concentration of total IgG was quantified in the
purified preparation and an amount equivalent to what was
present in 500 ul of mouse antiserum were administered
intraperitoneally into mice on three consecutive days (day 21, 0
and +1) in a volume of 500 ul each. The mice were challenged
with M1 GAS on day 0.
VII. ELISA
ELISAs were performed for antibody determination as
essentially described [2]. NUNC immunoplates (Flow laborato-
ries) were coated with 100 ul of J8 or DT at 5 ug/ml in
carbonate-bicarbonate buffer (pH 9.6), overnight at 4uC, as
previously standardised in our laboratory. Serum samples were
assayed by plating 2-fold dilutions of a 1:100 dilution of serum.
The end point titers were determined as the highest dilution of
serum for which the OD was 3SD above the mean OD of
control wells containing serum from naı ¨ve mice. For quantitative
ELISA, standard curves were plotted using purified IgG
preparations and the IgG concentrations in unknown samples
were determined [14]. The concentrations of various IgG
isotypes were also determined.
VIII. In vivo CD4
+ and CD8
+ T- cell depletion
One week after the last boost with J8-DT or DT, selected
cohorts of mice received 0.3 mg of rat anti-CD4 (GK1.5) or 1 mg
of anti-CD8 (a ´-CD8-beta clone 53.5.8) mAb intraperitoneally
before (D22) and after (D+1, +4, +7) a GAS challenge. The dose
and time-course for both depletions were previously optimised
using FACS to determine the degree of cell depletion (data not
shown). The schedule resulted in greater than 99% depletion of
CD4
+ T-cells and 95 to 97% deletion of CD8
+ T-cells as assessed
by FACS analysis. Control groups included J8-DT immunized
mice, which were untreated or treated with normal rat IgG (nRIg),
and PBS immunized mice which were treated with anti-CD4/anti-
CD8 mAb or nRIg.
Statistical Analysis
The geometric mean and SEM were calculated using standard
formulas. Mann-Whitney test was used to compare the propor-
tions of surviving mice challenged with GAS. P,0.05 was
considered to be statistically significant.
Results
1. Antibody/isotypes response to immunogen
Immunization of BALB/c mice with J8-DT/alum induced
production of IgG antibodies that recognised J8 peptide. As
Protection Mechanism of J8-DT
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an increase in J8-specific IgG titres (Figure 1a). After three boosts,
J8-specific IgG titers were approximately 10
6 and sera were used
for passive transfer. Immunization with DT produced high level of
anti-DT IgG which showed no specificity for the J8 peptide in
ELISA. To further characterize the antibody responses, antibody
isotypes were quantified. Immunization of BALB/c mice with J8-
DT/alum induced significantly higher level of IgG1 than of IgG2a
or IgG2b. In general, the levels of IgG3 were undetectable
(Figure 1b).
2. Passive transfer of immunity in naive mice by J8-DT
antisera
2.1 Passive transfer of murine J8-DT antisera into BALB/
c mice. In order to determine the protective efficacy of
antibody, J8-DT, DT or PBS antisera were passively transferred
into naı ¨ve mice, which were subsequently challenged with M1
GAS. First we confirmed that two injections of antiserum would
result in an immediate titre of antibody in the recipients. As
depicted in Figure 2a, all recipient mice had high levels of anti-J8
IgG antibodies when tested on day 0 after the second serum
administration. Following a lethal challenge, none of the immune
mouse serum recipients nor the immunized mice showed any sign
of illness during the first 24 hrs of infection. On the contrary, the
control mice that received DT or PBS antisera showed signs of
morbidity (ruffled fur, lack of response to external stimulus,
hunched posture). Passive transfer of J8-DT antisera into BALB/c
mice significantly protected them from a lethal GAS challenge
compared to mice that received DT antiserum (p,0.05)
(Figure 2b). Mice receiving DT antisera did not have
significantly higher rates of survival (p.0.05) and died within 5
days of challenge as did the controls that received PBS antisera. In
contrast mice receiving J8-DT antisera (with an end point J8-
specific IgG concentration of at least 100 ug/ml or more) were
protected against a lethal challenge of GAS. Antibody isotyping
showed a preponderance of IgG1 in transferred mouse serum
(Figure 2c). The lower level of protection (60%) in J8-DT
antiserum recipients compared to vaccinated-challenged controls
(80%) suggested a possible involvement of some other factors
beside transferred antibodies in vaccine mediated protection. We
also noted that the level of J8-specific IgG fell dramatically soon
after challenge both in donor and antiserum recipient mice
(Figure 2d). However, donor immunized mice having their
immune system primed through immunization, recover more
efficiently compared to antiserum recipient mice which is
suggestive of an ongoing active immune response in the host.
2.2 Passive transfer of J8-DT antisera to SCID mice. To
determine whether a de novo immune response of the host was
required for protection following passive transfer, these studies
were repeated in immunocompromised SCID mice (deficient in
both B and T-cells). J8 and DT-specific antibodies were found in
the serum of SCID mice post transfer (Figure 3a). Our results
demonstrated that BALB/c mice receiving J8-DT antiserum
survived significantly longer (p,0.05) than corresponding SCID
mice or BALB/C mice receiving DT antiserum (Figure 3b).
However, both mouse strains had similar level of passively
transferred IgG (Figures 2a, 3a). We noted that the majority of
the antibodies were consumed both in BALB/c and SCID
recipient mice soon after bacterial challenge (Figure 2d) but
BALB/c mice were able to continue synthesizing adequate levels
of IgG (as demonstrated by ELISA, Figure 2d). These data suggest
that an ongoing immune response may be required to protect mice
following passive transfer. The low level of protection offered by
DT antiserum was not significantly higher compared to PBS
antiserum recipient groups (p.0.05).
3. Antibodies to J8 are protective without the
involvement of DT
All the studies discussed so far have used J8-DT antibodies and
demonstrated their role in protection against GAS. To confirm that
J8 antisera are protective, experiments involving passive transfer of
J8 antiserum were conducted (Figure 4). We have shown previously
that B10.BR mice can respond to J8 alone [2]. Serum collected from
J8/CFA or J8-DT/CFA immunized B10.BR mice were passively
Figure 1. J8-specific serum IgG antibody response in BALB/c
mice immunized parenterally with J8-DT or DT. Cohorts of BALB/
c mice (n=10/group) received a primary immunization on day 0
followed by three boosts on day 21, 28 and 35. Serum samples were
collected before each vaccination and one week after last boost. The
geometric mean titres (GMT) of J8-specific serum IgG (a) and mean
concentrations of various J8-specific IgG isotypes in the final bleed
serum of BALB/c mice (b), determined by ELISA are shown.
doi:10.1371/journal.pone.0005147.g001
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equivalent levels of protection after a GAS challenge.
4. IgG is responsible for passive transfer of protection
To demonstrate that IgG is transferring protection, affinity
purified J8-DT or DT rabbit IgG were transferred passively into
BALB/c and SCID mice. Each naı ¨ve mouse received three doses
of 500 ug of rabbit IgG (from J8-DT or DT immunized rabbits)
(Figure 5a). Post-challenge, the mice receiving rabbit J8-DT IgG
(J8-DT R-IgG) were significantly protected (p,0.05) compared to
control mice receiving DT-specific IgG or normal rabbit IgG.
Groups of mice that received DT-specific IgG did not have
significantly higher rates of survival than did groups that received
rabbit IgG (p.0.05) (Figure 5b). We found that 500 ug J8-DT R-
IgG provided better protection than 250 ug or 125 ug of J8-DT
R-IgG (data not shown). IgG recipient BALB/c mice were better
protected than the IgG recipient SCID mice (Figure 5b). We again
noted that following challenge, as the passively transferred rabbit
antibodies were being depleted, the active host immune response
in BALB/c mice commenced resulting in the production of J8-
specific antibodies (Figure 5c). As expected this was not observed
in SCID mice. However, additional doses of R-J8-DT IgG were
able to significantly protect SCID mice compared to DT or
control IgG. The majority of the SCID mice in the cohort that
received routine scheduled doses of IgG (day 21, 0 and +1)
succumbed to infection by day 10 (20% survival) in contrast to
80% which survived after receiving additional doses of IgG on the
day 3, 5 and 8 (Figure 5d).
5. Requirement of T-cells for enhanced protection
5.1 Role of CD4
+ T-cells in protection induced by J8-
DT. To determine whether T-cells were involved in protection,
Figure 2. J8-specific serum IgG response and survival in mice following active and passive immunization. (a) J8-specific IgG
concentrations in serum of individual donor and recipient mice are shown, with mean concentration represented as horizontal bars. (b) Survival
following M1 GAS challenge in BALB/c mice after active (I/Ch) and/or passive (PT/Ch) immunization. Mice were challenged intraperitoneally with M1
GAS and their survival monitored for 10–12 days. Mann-Whitney test was used to compare the proportions of surviving mice. Significance is
represented as * p,0.05 and *** p,0.001. (c) Mean concentration of various J8-specific IgG isotypes in the serum of recipient BALB/c mice that
received J8-DT or DT antiserum. (d) J8-specific mean serum IgG concentrations in donor (BALB/c) and J8-DT antiserum recipient (BALB/c and SCID)
mice at different time-points post active and passive immunization followed by a lethal challenge.
doi:10.1371/journal.pone.0005147.g002
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+ T-cells were depleted from BALB/c mice post-
immunization by treatment with GK1.5 mAb before and after
challenge. This protocol resulted in 99% depletion (data not
shown).
Following GAS challenge, PBS immunized mice untreated or
that had been treated with GK1.5 or control antibodies (nRIgG)
experienced a fulminant infection and succumbed within three to
four days post infection (Figure 6a). In contrast, J8-DT immunized
mice that were depleted of CD4
+ T-cell had reduced protection
(44% survivors) compared to J8-DT immunized untreated mice
(75% survivors) or mice treated with nRIgG (75% survivors). Mice
in the DT immunized group, whether treated with GK1.5 or
nRIgG, had lower survival (12.5%) which was not significantly
higher (p.0.05) compared to PBS control. These data suggest that
an active immune response involving CD4
+ T-cells is required for
protection.
We further observed that by day 2 post-challenge antibody
levels had dropped dramatically in CD4
+ T-cell depleted, J8-DT
immunized mice and did not recover. In contrast, J8-DT
immunized mice either treated with nRIgG or untreated were
capable of generating antibodies following challenge (Figure 6b).
5.2 Role of CD8+ T-cells in protection induced by J8-
DT. Next, J8-DT immunized BALB/c mice were depleted of
CD8
+ T-cells and were subsequently challenged with M1 GAS.
The protocol resulted in .95% depletion of CD8
+ T-cells (data
not shown). Depletion of CD8
+ T-cell subset did not diminish
protection (Figure 7).
Discussion
In this study we have investigated the role of humoral and cell
mediated immune responses in protection induced by the GAS
vaccine candidate, J8-DT. We have previously shown that
immunization with J8-DT adsorbed onto alum induced high
levels of J8-specific antibodies, which were capable of protecting
outbred mice from a lethal challenge with GAS [3]. Here again we
have been able to reproduce similar results using inbred BALB/c
(H-2
d background) mice. This observation suggested to us that the
antibody response is an integral component of the protection
induced by J8-DT. Since previous studies were performed in
immunocompetent mice, we had not been able to exclude the
possibility of involvement of T-cells in protection. In this study we
have taken two different approaches to dissect the roles of
Figure 3. Antibody levels and percent survival of BALB/c and
SCID mice following active and/or passive immunization with
J8-DT, DT or PBS. (a) J8-specific serum IgG concentrations in donor
BALB/c or recipient SCID mice. Serum samples were collected post-
immunization (for donors) or post second administration of J8-DT or DT
antiserum (for recipients). J8-specific IgG concentrations in serum of
individual mice, are shown, with mean concentration represented as
horizontal bars. (b) Protection induced in BALB/c and SCID mice by J8-
DT following active (I/Ch) and/or passive immunization (PT/Ch). The
mice were challenged with M1 GAS and their survival monitored. Mann-
Whitney test was performed to compare the proportions of surviving
mice. Significance is represented as * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0005147.g003
Figure 4. Protection induced in B10.BR mice following passive
administration of J8/J8-DT/DT or PBS antisera from B10.BR
mice. Cohorts of B10.BR mice received antisera from mice immunized
with J8/J8-DT/DT or PBS in CFA. The antisera was passively
administered to B10.BR mice on three consecutive days (day 21, 0
and +1). The mice were challenged with M1 GAS on day 0 and their
survival monitored. I/Ch represent the cohort of mice that were
immunized with J8-DT. Significance is represented as * p,0.05, **
p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0005147.g004
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antibodies into immunocompetent (BALB/c and B10.BR) and
immunocompromised (SCID) mice, and, (ii) selective depletion of
T-cell subsets (CD4
+ and CD8
+ T-cells) following immunization.
Passive immunity has been investigated for a number of
organisms [4–8]. In the case of extracellular bacteria, passively
transferred antibodies are believed to be involved in agglutination
of bacteria or in alteration of the dissemination pattern of bacteria
from the site of inoculation [15]. For intracellular bacteria such as
Listeria and Mycobacteria, previous studies have indicated that
specific antibodies have little, if any role in protection [15]. In
contrast, some recent studies have shown that antibodies can be
effective against intracellular infection as in the case of E. chaffeensis
[16–18]. These studies suggest that the bacteria may not always
reside in the intracellular space and thus could become accessible
to serum antibodies.
We observed that passive transfer of J8-DT antisera into naı ¨ve
recipient mice resulted in significantly increased survival compared
to mice receiving DT antisera. However, the levels of protection in
passively immunized mice were never as high as in actively
immunized controls. This could be explained by the presence of
long-lived plasma cells (LLPC) and continuous antibody synthesis
in actively immunized mice. However, the diminished protection
observed in SCID mice compared to BALB/c mice could be
explained by the deficiency of B and T-cells in these mice and their
inability to mount a specific response to the bacterial challenge
following depletion of the passively transferred antibodies. Of
interest was the observation that SCID mice demonstrated
enhanced protection following transfer of additional doses of
rabbit J8-DT IgG.
It has been reported that efficient protection after vaccination
could only be acquired by elicitation of high level of long-lasting
anti-GAS specific antibodies [19]. Polyclonal antisera raised
against heat killed GAS was capable of transferring passive
protection which was dependent on the amount of anti-GAS
antibodies present in the immune serum and the time of
Figure 5. J8-specific IgG concentrations and protection in BALB/c and SCID mice following passive transfer of purified rabbit IgG.
Rabbits were multiply vaccinated with J8-DT and DT preparations in alum. Purified IgG (0.5 mg) was administered intraperitoneally into BALB/c and
SCID mice on each of three days (day 21, 0 and +1). Controls received similar amount of normal rabbit IgG (control R-IgG). The mice were challenged
on day 0 with M1 GAS and their survival monitored. (a) Demonstrates the concentration of J8-specific serum IgG in recipient BALB/c and SCID mice
post intraperitoneal transfer. (b) Survival of BALB/c and SCID mice following a M1 GAS challenge (significance is represented as * where p,0.05) (c)
Shows the concentration of J8-specific mouse (M) and rabbit (R) IgG in the serum of recipient mice at different time-points post antibody transfer
followed by M1 GAS challenge and (d) shows survival in SCID mice following additional doses (on day 3, 5 and 8) of J8-DT R-IgG or control R-IgG post
GAS challenge. The abbreviation DS1 represents dose schedule 1 (day 21, 0 and +1) whereas DS2 represents dose schedule 2 (Day 21, 0, +1, +3, +5
and 8). The mice were challenged on day 0 with M1 GAS and their survival monitored. Significance is represented as * where p,0.05.
doi:10.1371/journal.pone.0005147.g005
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suggested that high levels of anti-J8 antibodies are required for
protection [3].
The enhanced protection in actively immunized mice and
reduced protection in passively immunized SCID mice suggested
that T-cells may play a major role in vaccine mediated protection.
It has been reported that CD4
+ T-cells are important for
development of long term immunity to bacterial infections [20].
Development of the appropriate CD4
+ T-cell subset during an
immune response is critical for eradication of an infectious
organism. In vaccine mediated protection CD4
+ T-cells are
necessary to provide help to B-cells and CD8
+ T-cells, as well as
having effector function of their own in some situations. The CD4
+
T-cells bind to the epitopes presented by B-cells which results in
the development of clones of plasma cells secreting antibodies
against the antigenic material. We have observed here that
immunized mice, when depleted of CD4
+ T-cells have reduced
level of protection, suggesting that CD4
+ (helper) T-cells are
important for vaccine mediated protection. It has been shown in
the case of rabies vaccine that passive antibody alone is poorly
effective unless supplemented by transfer of CD4
+ and CD8
+ T-
cells [21,22]. Similar findings have been reported in the case of a
malaria vaccine candidate where an absolute requirement of
CD4
+ T-cells was observed to enhance passive immunity [23]. In
contrast, previous studies involving S. pneumoniae demonstrated
CD4
+ T-cell independent passive protection. [15]. These studies
utilized polysaccharide antigens which are known to be thymus
independent and have ability to stimulate B-cells directly. In this
study the conjugation of J8 to DT generates a T-cell dependent
antibody response that leads to the production of protective
antibodies and possibly immunologic memory.
In summary, we have demonstrated that purified IgG from J8-
DT immunized donor animals can protect naı ¨ve recipient mice
including immunocompromised SCID mice. Taken together these
data demonstrates the potential utility of J8-specific IgG in passive
immunotherapy for the treatment of GAS diseases.
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Figure 6. Antibody levels and percent survival of BALB/c mice
immunized and depleted/undepleted of CD4
+ T-cells. BALB/c
mice were immunized with J8-DT/DT or PBS parenterally. For in vivo
depletion of CD4
+ T-cells mice were administered with 0.3 mg of anti-
CD4 (GK1.5) antibodies intraperitoneally over a set time-course before
and after challenge as shown. Protection (a) and antibody concentra-
tions before and after challenge (b) in J8-DT immunized and CD4
+ T-
cell depleted/undepleted BALB/c mice are shown. The abbreviation I/
Ch stands for immunized/undepleted mice (positive controls). Signif-
icance is represented as * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0005147.g006
Figure 7. Survival of BALB/c mice immunized and depleted/
undepleted of CD8
+ T-cells. BALB/c mice were immunized with J8-
DT/DT or PBS parenterally. For in vivo depletion of CD8
+ T-cells mice
were administered with 1 mg of anti-CD8 (a-CD8-beta clone 53.5.8)
mAb intraperitoneally over a set time-course before and after GAS
challenge. Survival in J8-DT immunized and CD8
+ T-cell depleted/
undepleted BALB/c mice are shown. The abbreviation D stands for
immunized/depleted mice whereas U/D represents immunized/unde-
pleted. Significance is represented as * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0005147.g007
Protection Mechanism of J8-DT
PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e5147References
1. Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, et al. (1996)
Mapping a conserved conformational epitope from the M protein of group A
streptococci. Pept Res 9: 12–20.
2. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, et al. (1997) Mapping the
minimal murine T cell and B cell epitopes within a peptide vaccine candidate
from the conserved region of the M protein of group A streptococcus. Int
Immunol 9: 1723–1733.
3. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, et al. (2003)
Protection against group A streptococcus by immunization with J8-diphtheria
toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to
protection. J Infect Dis 187: 1598–1608.
4. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE (2001) Passive transfer of
antibodies protects immunocompetent and immunodeficient mice against lethal
Ebola virus infection without complete inhibition of viral replication. Journal of
Virology 75: 4649–4654.
5. Beedham RJ, Turnbull PCB, Williamson ED (2001) Passive transfer of
protection against Bacillus anthracis infection in a murine model. Vaccine 19:
4409–4416.
6. Kennedy BJ, Novotny LA, Jurcisek JA, Lobet Y, Bakaletz LO (2000) Passive
transfer of antiserum specific for immunogens derived from a nontypeable
Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after
heterologous challenge. Infection and Immunity 68: 2756–2765.
7. Smith DJ, King WF, Godiska R (2001) Passive transfer of immunoglobulin Y
antibody to Streptococcus mutans glucan binding protein B can confer
protection against experimental dental caries. Infection and Immunity 69:
3135–3142.
8. Liu MY, Zhu H, Zhang JL, Lei BF (2007) Active and passive immunizations
with the streptococcal esterase Sse protect mice against subcutaneous infection
with group A Streptococci. Infection and Immunity 75: 3651–3657.
9. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J (2006) Human
intravenous immunoglobulin for experimental streptococcal toxic shock:
bacterial clearance and modulation of inflammation. Journal of Antimicrobial
Chemotherapy 58: 117–124.
10. Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A (2004) Differences
in potency of intravenous polyspecific immunoglobulin G against streptococcal
and staphylococcal superantigens: Implications for therapy of toxic shock
syndrome. Clinical Infectious Diseases 38: 836–842.
11. Houghten RA (1985) General method for the rapid solid-phase synthesis of large
numbers of peptides: specificity of antigen-antibody interaction at the level of
individual amino acids. Proc Natl Acad Sci U S A 82: 5131–5135.
12. Coligan JE, Kruisbeek AM, Margulie DH, Shevach EM, Strober W Current
protocols in immunology. New York: John Wiley.
13. Pandey M, Batzloff M, Good M (2006) Investigation of the factors affecting
catabolism of antibodies raised againstt a vaccine candidate based on the
conserved region of the M-protein. International Congress Series 1289:
336–339.
14. Bjorkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin Antibody-
Levels and the Outcome of Illness During an Outbreak of Diphtheria among
Alcoholics. Scandinavian Journal of Infectious Diseases 18: 235–239.
15. Rhinehartjones TR, Fortier AH, Elkins KL (1994) Transfer of Immunity against
Lethal Murine Francisella Infection by Specific Antibody Depends on Host
Gamma-Interferon and T-Cells. Infection and Immunity 62: 3129–3137.
16. Li JSY, Winslow GM (2003) Survival, replication, and antibody susceptibility of
Ehrlichia chaffeensis outside of host cells. Infection and Immunity 71:
4229–4237.
17. Ohashi N, Zhi N, Zhang YL, Rikihisa Y (1998) Immunodominant major outer
membrane proteins of Ehrlichia chaffeensis are encoded by a polymorphic
multigene family. Infection and Immunity 66: 132–139.
18. Winslow GM, Yager E, Shilo K, Volk E, Reilly A, et al. (2000) Antibody-
mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia
chaffeensis during active infection. Infection and Immunity 68: 2187–2195.
19. Siegert J, Sastalla I, Chhatwal GS, Medina E (2006) Vaccination equally enables
both genetically susceptible and resistant mice to control infection with group A
streptococci. Microbes and Infection 8: 347–353.
20. Kar S, Metz C, McMahon-Pratt D (2005) CD4(+) T cells play a dominant role
in protection against new world leishmaniasis induced by vaccination with the p-
4 amastigote antigen. Infection and Immunity 73: 3823–3827.
21. Hemachudha T, Mitrabhakdi E, Wilde H, Vejabhuti A, Siripataravanit S, et al.
(1999) Additional reports of failure to respond to treatment after rabies exposure
in Thailand. Clinical Infectious Diseases 28: 143–144.
22. Plotkin SA (2000) Rabies. Clinical Infectious Diseases 30: 4–12.
23. Hirunpetcharat C, Vukovic P, Xue QL, Kaslow DC, Miller LH, et al. (1999)
Absolute requirement for an active immune response involving B cells and Th
cells in immunity to Plasmodium yoelii passively acquired with antibodies to the
19-kDa carboxyl-terminal fragment of merozoite surface protein-1. Journal of
Immunology 162: 7309–7314.
Protection Mechanism of J8-DT
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5147